John Wahren
Hoofd Techniek/Wetenschap/O&O bij Creative Peptides Sweden AB
Actieve functies van John Wahren
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Creative Peptides Sweden AB
 Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Hoofd Techniek/Wetenschap/O&O | - | - |
| Karolinska Institutet | Corporate Officer/Principal | 24-06-2009 | - |
Loopbaan van John Wahren
Eerdere bekende functies van John Wahren
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| University of Lausanne | Corporate Officer/Principal | 01-01-1984 | 01-01-1984 |
Cebix, Inc.
 Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Directeur/Bestuurslid | 24-06-2009 | - |
| Hoofd Techniek/Wetenschap/O&O | 24-06-2009 | - | |
| Oprichter | 13-04-2010 | - |
Opleiding van John Wahren
| Karolinska Institutet | Doctorate Degree |
Statistieken
Internationaal
| Zweden | 3 |
| Verenigde Staten | 2 |
| Zwitserland | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Creative Peptides Sweden AB
Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Health Technology |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
- Beurs
- Insiders
- John Wahren
- Ervaring
